U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07236112) titled 'Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate Cancer' on Nov. 13.
Brief Summary: TRDC002 uses a radioactive form (64Cu) to trace the PSMA positive prostate cancer. The purpose of this study is to investigate TRDC002 as a PSMA PET tracer to localize PSMA positive lesions in adult patients with recurrent or metastatic prostate cancer. We plan to assess the PSMA PET/CT image quality following administration of two dose levels of TRDC002 to determine an acceptable dose and optimal acquisition time for obtaining diagnostic quality PET/CT images. The safety and tolerability, PK, biodistribution, dosimetry of TR...